文献速递腹部胸部技术与安全PETCT

IV期结直肠癌中KRAS突变与18F-FDG摄取的相关性

Correlation between KRAS mutation and 18F-FDG uptake in stage IV colorectal cancer.
PubMed 文献 · Abdom Radiol (NY) · 2017-01-01

本研究评估IV期结直肠癌患者KRAS突变与18F-FDG PET/CT原发灶摄取指标及转移模式的相关性。KRAS突变阳性40例(43%),突变组原发灶SUVmax、SUVmean、TLG均高于野生型组,且肺转移更常见,野生型组肝转移更常见。

要点

  • IV期CRC原发灶SUVmax较高(14.0 vs 11.2)与KRAS突变相关。
  • KRAS突变组肺转移比例高于野生型组(50.0% vs 22.6%)。
  • 野生型KRAS组肝转移比例高于突变组(81.1% vs 55.0%)。

核心结论

  • IV期CRC中,KRAS突变患者较野生型KRAS患者原发灶18F-FDG摄取更高且肺转移更常见,野生型KRAS患者肝转移更常见。

研究设计与样本

  • 研究纳入接受18F-FDG PET/CT分期及KRAS突变分析的IV期结直肠癌患者,于PET图像上在原发灶勾画感兴趣体积(VOI)获取SUVmax、SUVmean、MTV、TLG,并与原发灶KRAS突变及转移部位进行相关性分析。

诊断标准与关键数值

  • KRAS突变阳性40例(43%)。
  • KRAS突变组原发灶SUVmax 14.0 vs 野生型组11.2(p=0.004)。
  • KRAS突变组原发灶SUVmean 5.3 vs 野生型组4.7(p=0.005)。
  • KRAS突变组原发灶TLG 301.4 vs 野生型组205.5(p=0.023)。
  • 多因素分析中,原发肿瘤部位(OR 3.92,p=0.07)与KRAS突变(OR 2.45,p=0.09)为肺转移模型中的显著因素。

局限性

  • 多因素分析中肺转移模型的原发肿瘤部位OR 3.92(p=0.07)与KRAS突变OR 2.45(p=0.09)未达统计学显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: The purpose of this study is to evaluate the correlation between KRAS mutation, 18F-FDG uptake, and metastatic pattern in advanced stage colorectal cancer (CRC) patients.

METHODS: Medical records of stage IV CRC patients who underwent 18F-FDG PET/CT for staging and KRAS mutation analysis were selected. On PET scans, a volume of interest (VOI) was drawn on the primary lesion. 18F-FDG indices (SUVmax, SUVmean, MTV, TLG) of the primary lesions were obtained and correlated with KRAS mutation of the primary lesion. Also, metastatic sites were recorded. Association between metastatic pattern and KRAS expression and FDG indices were analyzed.

RESULTS: KRAS mutation was positive in 40 (43%) patients. Evaluation of FDG indices showed that higher SUVmax (14.0 vs. 11.2, p = 0.004), higher SUVmean (5.3 vs. 4.7, p = 0.005), and higher TLG (301.4 vs. 205.5, p = 0.023) were predictive of KRAS mutation compared to wild-type (WT) KRAS. Lung metastasis was more frequently involved in patients with KRAS mutation (50.0% vs. 22.6%, p = 0.006), and liver metastasis was more frequently involved in patients with WT KRAS (81.1% vs. 55.0%, p = 0.007). Multivariate analysis showed that primary tumor location (OR 3.92, p = 0.07) and KRAS mutation (OR 2.45, p = 0.09) were significant factors in lung metastasis model.

CONCLUSION: KRAS mutation patients had more frequent lung metastasis and had higher 18F-FDG uptake compared to WT KRAS in stage IV CRC.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Cho A, Jo K, Hwang SH, et al. Correlation between KRAS mutation and 18F-FDG uptake in stage IV colorectal cancer. Abdom Radiol (NY). 2017. PMID: 28161825. doi:10.1007/s00261-017-1054-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。